Metformin Use in Cardiac Fibrosis in PAI-1 Deficiency
Status:
Not yet recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of metformin, in patients 18-65 years of age
with homozygous plasminogen activator inhibitor-1 (PAI-1) deficiency, with or without cardiac
fibrosis, for a period of 60 months. The starting dose of metformin will be 500 mg up to a
maximum dose of 2000 mg for a period of 5 years with the aim to assess the safety and
efficacy of metformin on prevention/stabilization or regression of cardiac fibrosis in a
Treated population vs. a Comparison population.